site of BCR-ABL tyrosine kinase (Nagar et al., 2002) . IM binds to the BCR-ABL tyrosine kinase ATP binding site and lead to inhibition of the tyrosine autophosphorylation and, in turn, phosphorylation of its substrates, thereby preventing the enzyme activity of the tyrosine kinase protein semi-competitively (Kantarjian et al., 2010) .
Introduction
Chronic Myeloid Leukemia (CML) is associated with the Philadelphia chromosome, which is caused by a reciprocal translocation between chromosomes 9 and 22 (Kurzrock et al., 1988; Melo, 1996) . The t(9;22) (q34;q11) translocation results in constitutively active breakpoint cluster region-Abelson (BCR-ABL) tyrosine kinase and plays a central role in the pathogenesis of CML (Baccarani et al., 2012) . The use of tyrosine-kinase inhibitors (TKIs) to inhibit BCR-ABL protein in CML is one the major milestones in modern oncology. Imatinib Mesylate (IM) was approved as first line therapy for newly diagnosed CML in chronic phase and prolonged survival of CML patient (Hochhaus et al., 2009) . It is a selective inhibitor of the BCR-ABL tyrosine kinase that binds competitively to the adenosine triphosphate (ATP) binding
The occurrence of resistance mutations of the BCR-ABL1 kinase domain are the most common cause of IM treatment failure in CML patients by shifting its equilibrium toward the open or active conformation (Nagar et al., 2002) . Among them, the 'gatekeeper' mutation, T315I, affects catalytic domain of ABL kinase and cause complete resistance to treatment (Gorre et al., 2001) . The T315I mutation results in a threonine (T) to an isoleucine (I) change at amino acid position 315. The second-generation TKIs, including dasatinib and nilotinib, have been shown to inhibit most IM-resistant BCR-ABL mutations, except for T315I (Guilhot et al., 2007; Hochhaus et al., 2007; Kantarjian et al., 2007; Hughes et al., 2009; Muller et al., 2009 ). The inclusion of other treatment modalities such as moving to allogeneic stem cell transplantation, or testing an investigational compound is required in affected patients (Pavlu et al., 2011) .
The understanding of BCR-ABL mutational status is very useful in order to optimize therapeutic decision. Mutations Screening for T315I mutation in all CML patients resistant to TKIs treatment should be performed as early as possible to detect the lowest levels of the mutant (Baccarani et al., 2009; Jones et al., 2009 ). This study aimed to determine the frequency of BCR-ABL T315I mutation in Malaysian patients with CML.
Materials and Methods

Subjects
A total of 285 CML patients with IM failure were included in the study. They were recruited from various hospitals in Peninsular Malaysia, Sabah, and Sarawak in 2013 to 2016. These patients were those in chronic, accelerated or blast phase, which has been treated with IM (Gleevec, Novartis) as first line treatment. According to European LeukemiaNet recommendations, failure means that the patient should be moved to other treatments because the response is such that the patient showed significant risk of progression and death (Baccarani et al., 2015) . Bone marrow aspirate or peripheral blood samples were obtained from these patients and screened for BCR-ABL T315I mutation.
Genomic DNA Extraction
Genomic DNA was extracted from peripheral blood using QiAmp® DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany) according to manufacturer's instructions. The quantity and ratio of absorbance at 260 nm and 280 nm (A260/280) of purified gDNA was determined with a spectrophotometer (Nanodrop, USA).
Mutation analysis
Samples were subjected to mutation analysis using qualitative qPCR AmoyDx BCR-ABL T315I kit (Amoy Diagnostics Co., LTD, China) according to manufacturer's recommendation. AmoyDx BCR-ABL T315I kit was performed in tubes, on an Applied Biosystems 7500 Real-time PCR Machine (Life Technologies, USA). Each sample was tested for the presence of T315I mutation. 2 ng of gDNA was used per reaction and the reaction volume was 35 µl.
The cycling conditions consisted of an initial denaturation step at 95 time. If the amplification curve was not classic S-curve or if Ct value was ≥29, the result was determined as wild type (mutation negative). This kit provides a highly sensitive molecular technique to detect as low as 1% BCR-ABL T315I mutation DNA in background of 99% normal DNA at 5 ng sample DNA amount, while ensuring that false negatives are minimized.
Results
The demographic profiles of these 285 CML patients are shown in Tables 1. Following the patients' characteristics, 63.2% of patients were male and 36.8% were female. The age of patient varies between 2 to 81 years old with mean value 42.2 years old. From a total number of patients, 58.9% were Malays, 22.5% Chinese, 10.2% Indian and 8.4% other races.
Fifteen out of 285 samples (5.26%) were positive for T315I mutations after amplification with real-time PCR assay, in which 13 samples were male (Table 1) . Malay patients constitute the highest (n=9) followed by Chinese, Indian and other races (Table 1) . From the total number of positive samples, six patients were in accelerated phase (AP), four in chronic phase (CP) and five in blast crisis (BC).
Discussion
BCR-ABL kinase domain mutations had been reported to occur in 50% of patients who develop resistance to IM (Jabbour et al., 2006) . Identification of mutational analysis at IM failure is important as it can facilitate selection of the most appropriate therapy to prevent or overcome resistance (Bixby and Talpaz, 2009). The common clinically relevant imatinib-resistant mutations are G250E, Y253F/H, E255K/V, T315I, M351T and F359V (Soverini et al., 2006) . Second-generation ABL TKIs dasatinib (Shah et al., 2004) , nilotinib (Weisberg et al., 2005) , bosutinib (Golas et al., 2003) and bafetinib (Kimura et al., 2005) were developed for the treatment of imatinib-resistant patients. Unfortunately, these second-generation drugs are ineffective against the T315I mutation (Kaleem et al., 2015) . Therefore, a third-line TKIs ponatinib was introduced to overcome IM failure and further improve the inhibitory effect (O'Hare et al., 2009 In conclusion, BCR-ABL T315I mutation is the most severe form of tyrosine kinase domain (TKD) mutation as it causes decrease affinity for TKIs and thereby promotes shortening of patients' survival. Therefore, detection of T315I mutation by molecular techniques are clinically useful in the selection of appropriate treatment strategies to prevent disease progression in CML patients. Further study on the full spectrum of TKD mutations will be performed to look at different level of resistance in order to guide therapy in CML patients.
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The BCR-ABL kinase domain mutations that located in the IM binding domain (amino acids 315-317) are reported to have association with IM-resistance (Jones et al., 2009 ). These amino acids form a critical hydrogen bonds with IM. The substitution of threonine to isoleucine at residue 315 (T315I), thus impaired IM placement within the ATP-binding pocket of the BCR-ABL gene (Gorre et al., 2001; Nagar et al., 2002) . The T315I is reported to be the most frequent mutation related to resistance to most second generation TKIs. Elnahass et al., (2013) reported that 3.57% (1/28) T315I mutation was detected in IM resistant patients. The findings from Dhahi et al., (2013) showed the frequency of T315I mutation was detected in 1 of 34, 3.03% CML patients in accelerated phase after IM failure. Both studies were performed using allele-specific oliogonucleotide-PCR for mutation screening (Elnahass et al., 2013) . A study conducted by Elias et al., (2012) reported that T315I mutation was detected in 8 of 40 cases (20%) in Philadelphia chromosome (Ph) positive CML patients who showed resistance to IM. In addition, Roche-Lestienne et al., (2002) revealed that 12.5% (3/24) of IM-resistant patients showed positive T315I. The T315I mutation was detected in 5.2% (10/191) CML patients in the current study. Recently, the study on IM-resistant CML patients showed two of twenty-two patients had T315I mutation (Yap et al., 2017) . Our finding is in concomitant with a study conducted by other researchers in similar population (Elias et al., 2014) . In their study, 7.2% (9/125) T315I mutations were detected in Malaysian CML patients whom undergoing IM therapy.
The result of our study showed that 15 CML patients with T315I point mutations were in AP (n=6) and acute BC (n=5). T315I mutations were also detected in four CP CML patients, suggesting that point mutations in the ABL gene is not restricted to accelerated phase or acute blastic crisis patients (Roche-Lestienne et al., 2002) . Therefore, mutation screening in CP CML is recommended in patients with inadequate initial response or those with evidence of loss of response. It is also recommended at the time of progression to accelerated or blast phase (Jones et al., 2009 ). In our setting, a T315I mutation should lead to consideration of allogeneic haematopoetic stem cell
